```
=> d his

     (FILE 'HOME' ENTERED AT 09:12:02 ON 24 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 09:12:16 ON 24 MAR 2009
L1             STRUCTURE UPLOADED
L2             0 S L1
L3             5 S L1 FULL

=> d que l3 stat
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3             5 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED      21 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01


=> d 1-5 ide can
```

L3 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1117698-29-9 REGISTRY
ED Entered STN: 09 Mar 2009
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone], sodium salt (1:2) (CA INDEX NAME)
MF C25 H22 N8 O2 . 2 Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
CRN (1033040-23-1)



●2 Na

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 150:229703

L3 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1033040-23-1 REGISTRY
ED Entered STN: 08 Jul 2008
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)
MF C25 H22 N8 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 150:229703

REFERENCE 2: 150:160099

REFERENCE 3: 149:513836

REFERENCE 4: 149:282993

REFERENCE 5: 149:45179

L3 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
RN 851606-62-7 REGISTRY
ED Entered STN: 03 Jun 2005
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl-3H-pyrazol-3-one (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]azo]-5-methyl-3H-pyrazol-3-one (1:1) (9CI)
MF C25 H21 N8 O2 . C5 H14 N O
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSRESEARCH, SYNTHLINE, TOXCENTER, USAN, USPATFULL

CM 1

CRN 851606-61-6
CMF C25 H21 N8 O2



CM 2

CRN 62-49-7
CMF C5 H14 N O



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:463730

L3 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
RN 851606-61-6 REGISTRY
ED Entered STN: 03 Jun 2005
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl-, ion(1-) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3H-Pyrazole-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]azo]-5-methyl-, ion(1-) (9CI)
MF C25 H21 N8 O2
CI COM
SR CA
LC STN Files: IMSDRUGNEWS, IMSRESEARCH, SYNTHLINE



L3 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2009 ACS on STN
RN 376592-42-6 REGISTRY
ED Entered STN: 19 Dec 2001
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]azo]-5-methyl- (9CI)
OTHER NAMES:
CN Totrombopag
MF C25 H22 N8 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, IMSRESEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 149:548251

REFERENCE 2: 146:428547

REFERENCE 3: 142:463730

REFERENCE 4: 141:406144

REFERENCE 5: 136:5987

```
=> fil capl
FILE 'CAPLUS' ENTERED AT 09:14:59 ON 24 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 24 Mar 2009  VOL 150 ISS 13
FILE LAST UPDATED: 23 Mar 2009  (20090323/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l3
L4          10 L3

=> d l-10 bib abs hitstr
```

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:207399 CAPLUS
DN 150:229703
TI Methods using non-peptide thrombopoietin (TPO) receptor agonists for treating cardiovascular diseases/injuries
IN Erickson-Miller, Connie; Jenkins, Julian
PA USA
SO U.S. Pat. Appl. Publ., 21pp., Cont.-in-part of U.S. Ser. No. 554,811.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20090048318	A1	20090219	US 2008-256669	20081023
	WO 2004096154	A2	20041111	WO 2004-US13468	20040429
	WO 2004096154	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20070105824	A1	20070510	US 2006-554811	20061110
PRAI	US 2003-466540P	P	20030429		
	US 2003-471554P	P	20030519		
	US 2003-495034P	P	20030814		
	US 2004-549977P	P	20040304		
	US 2004-554581P	P	20040319		
	US 2004-556390P	P	20040325		
	WO 2004-US13468	W	20040429		
	US 2006-554811	A2	20061110		

AB The invention discloses a method for treating cardiovascular disease/injury in a mammal (including a human) in need thereof, which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist.

IT 1033040-23-1 1033040-23-1D, salts 1117698-29-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-peptide TPO receptor agonists for treatment of cardiovascular diseases/injuries)

RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 1117698-29-9 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone], sodium salt (1:2) (CA INDEX NAME)



●2 Na

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:93143 CAPLUS
DN 150:160099
TI Use of a thrombopoietin (TPO) cell cycle activator and a chemotherapeutic agent for the treatment of cancer
IN Erickson-Miller, Connie
PA USA
SO U.S. Pat. Appl. Publ., 22pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20090022814	A1	20090122	US 2008-166686	20080702
WO 2008101141	A2	20080821	WO 2008-US54046	20080215
WO 2008101141	A3	20081016		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI	US 2007-890236P	P	20070216
	US 2007-892552P	P	20070302
	US 2007-908205P	P	20070327
	US 2007-949347P	P	20070712
	US 2007-952289P	P	20070727
	US 2007-969192P	P	20070831
	US 2007-977216P	P	20071003
	WO 2008-US54046	A2	20080215

AB The invention discloses a method for treating cancer in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a TPO cell cycle activator and a chemotherapeutic agent to such mammal.

IT 1033040-23-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TPO cell cycle activator and chemotherapeutic agent for treatment of cancer)

RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1338135 CAPLUS
DN 149:513836
TI Preparation of hydroxy-1-azo-derivatives as thrombopoietin mimetics for pharmaceutical use
IN Hayes, Jerome Francis
PA Smithkline Beecham Corp., USA
SO PCT Int. Appl., 15pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008134338	A1	20081106	WO 2008-US61225	20080423
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2007-913601P	P	20070424		

OS MARPAT 149:513836
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Hydroxy-1-azo-benzene derivs. (I) as thrombopoietin (TPO) mimetics, wherein Z = COOH or tetrazol, are prepared by treating compound (II) (X = Cl, Br, I, Y = NO2, NH2, R = alkyl) with a boronic acid to form compds. (III) (Y = NH2, NO2, G = aryl), and then converting III to compds. I. Also invented are novel intermediates used in the novel processes. Also invented are pharmaceutical compns. comprising compds. made by novel processes.

IT 1033040-23-1P
RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxy-1-azo-derivs. as thrombopoietin mimetics for pharmaceutical use)

RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1138522 CAPLUS
DN 149:548251
TI Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor
AU Alper, Phil B.; Marsilje, Thomas H.; Mutnick, Daniel; Lu, Wenshuo; Chatterjee, Arnab; Roberts, Michael J.; He, Yun; Karanewsky, Donald S.; Chow, Donald; Lao, Jianmin; Gerken, Andrea; Tuntland, Tove; Liu, Bo; Chang, Jonathan; Gordon, Perry; Seidel, H. Martin; Tian, Shin-Shay
CS Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, 92121, USA
SO Bioorganic & Medicinal Chemistry Letters (2008), 18(19), 5255-5258
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
AB A novel series of benzo[a]carbazole-based small mol. agonists of the thrombopoietin (Tpo) receptor is reported. Starting from a 3.4 μM high throughput screen hit, members of this series have been identified which are full agonists with functional potency <50 nM and oral bioavailability in mice.
IT 376592-42-6, Totrombopag
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery and biol. evaluation of benzo[a]carbazole-based small mol. agonists of thrombopoietin receptor)
RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1008939 CAPLUS
DN 149:282993
TI Thrombopoietin receptor agonist for treatment of cancer
IN Erickson-Miller, Connie Lynn
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 53pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008101141	A2	20080821	WO 2008-US54046	20080215
	WO 2008101141	A3	20081016		
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20090022814	A1	20090122	US 2008-166686	20080702
PRAI	US 2007-890236P	P	20070216		
	US 2007-892552P	P	20070302		
	US 2007-908205P	P	20070327		
	US 2007-949347P	P	20070712		
	US 2007-952289P	P	20070727		
	US 2007-969192P	P	20070831		
	US 2007-977216P	P	20071003		
	WO 2008-US54046	A2	20080215		

OS MARPAT 149:282993
AB Invented is a method of treating cancer and pre-cancerous syndromes in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.
IT 1033040-23-1 1033040-23-1D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thrombopoietin receptor agonist for treatment of cancer)
RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)


OH
NH
N
O
Me
Me
Me
N
N
N
N
H

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:735884 CAPLUS
DN 149:45179
TI TPO receptor agonist combination with other antiviral therapy for the treatment of viral diseases
IN Erickson-Miller, Connie L.; Jenkins, Julian; Theodore, Dickens
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 50pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008073864	A1	20080619	WO 2007-US86918	20071210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2006-869583P	P	20061212		

OS MARPAT 149:45179
AB The invention discloses a method for treating viral diseases, particularly hepatitis C, in a human, in need thereof which comprises the administration of a combination of therapeutically active agents selected from a TPO receptor agonist and an antiviral therapy selected from an α-interferon, ribavirin, a ribavirin analog, and an HCV antiviral to such human.
IT 1033040-23-1 1033040-23-1D, salts or esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TPO receptor agonist combination with other antiviral therapy for treatment of viral diseases)
RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RN 1033040-23-1 CAPLUS
CN 1H-Pyrazole-4,5-dione, 1-(3,4-dimethylphenyl)-3-methyl-, 4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]hydrazone] (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:435850 CAPLUS
DN 146:428547
TI Non-peptide thrombopoietin receptor agonist for the preservation of platelet efficacy during storage
IN Erickson-Miller, Connie Lynn
PA SmithKline Beecham Corporation, USA
SO PCT Int. Appl., 34pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007044982	A2	20070419	WO 2006-US40494	20061013
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	EP 1942906	A2	20080716	EP 2006-826085	20061013
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009511603	T	20090319	JP 2008-535784	20061013
	US 20080286865	A1	20081120	US 2008-89978	20080411
PRAI	US 2005-726249P	P	20051013		
	WO 2006-US40494	W	20061013		

OS MARPAT 146:428547
AB This invention relates to method for the preservation of human platelet lifespan and/or efficacy during storage which comprises the addition of an effective amount of a non-peptide TPO receptor agonists to a storage solution containing human platelets.
IT 376592-42-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-peptide thrombopoietin receptor agonist for preservation of platelet efficacy during storage)
RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:405369 CAPLUS
DN 142:463730
TI Preparation of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline salt
IN Brook, Christopher S.; Ping, Li-Jen J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005041867	A2	20050512	WO 2004-US34944	20041021
WO 2005041867	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285462	A1	20050512	AU 2004-285462	20041021
CA 2543216	A1	20050512	CA 2004-2543216	20041021
EP 1684748	A2	20060802	EP 2004-796011	20041021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015704	A	20061219	BR 2004-15704	20041021
CN 1897937	A	20070117	CN 2004-80038488	20041021
JP 2007509159	T	20070412	JP 2006-536801	20041021
IN 2006DN02031	A	20070622	IN 2006-DN2031	20060413
US 20070072922	A1	20070329	US 2006-576411	20060420
MX 2006004483	A	20060620	MX 2006-4483	20060421
KR 2006095761	A	20060901	KR 2006-707688	20060421
NO 2006002111	A	20060718	NO 2006-2111	20060511
PRAI US 2003-513481P	P	20031022		
WO 2004-US34944	W	20041021		

OS CASREACT 142:463730
GI



I

AB An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one (I), is prepared by treating 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one with choline hydroxide. The

compound I is useful as an agonist of thrombopoietin receptor in enhancing platelet production, particularly in the treatment of thrombocytopenia. A tablet and injectable parenteral composition containing I are described.

IT 851606-62-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrozol-3-one choline salt as thrombopoietin receptor agonist)

RN 851606-62-7 CAPLUS

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl-3H-pyrazol-3-one (1:1) (CA INDEX NAME)

CM 1

CRN 851606-61-6
CMF C25 H21 N8 O2



CM 2

CRN 62-49-7
CMF C5 H14 N O

IT 376592-42-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrozol-3-one choline salt as thrombopoietin receptor agonist)

RN 376592-42-6 CAPLUS

CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:965013 CAPLUS
DN 141:406144
TI Methods for treating degenerative diseases/injuries using nonpeptide thrombopoietin receptor agonists
IN Erickson-Miller, Connie L.; Jenkins, Julian
PA SmithKline Beecham Corporation, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096154	A2	20041111	WO 2004-US13468	20040429
	WO 2004096154	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1622609	A2	20060208	EP 2004-760459	20040429
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006525352	T	20061109	JP 2006-514185	20040429
	US 20070105824	A1	20070510	US 2006-554811	20061110
	US 20090048318	A1	20090219	US 2008-256669	20081023
PRAI	US 2003-466540P	P	20030429		
	US 2003-471554P	P	20030519		
	US 2003-495034P	P	20030814		
	US 2004-549977P	P	20040304		
	US 2004-554581P	P	20040319		
	US 2004-556390P	P	20040325		
	WO 2004-US13468	W	20040429		
	US 2006-554811	A2	20061110		

OS MARPAT 141:406144
AB Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal. An injectable form for administering the present invention is produced by stirring 1.5 % by weight of 4'-[N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino]-3'-hydroxy biphenyl-3-carboxylic acid in 10 % by volume propylene glycol in water.
IT 376592-42-6
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as nonpeptide TPO receptor agonist; nonpeptide thrombopoietin receptor agonists for treatment of degenerative diseases/injuries)
RN 376592-42-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:868162 CAPLUS
DN 136:5987
TI Thrombopoietin mimetics
IN Duffy, Kevin J.; Erickson-Miller, Connie L.; Eppley, Daniel F.; Jenkins, Julian; Luengo, Juan I.; Liu, Nannan; Price, Alan T.; Shaw, Antony N.; Visouneau, Sophie; Wiggall, Kenneth
PA SmithKline Beecham Corporation, USA; Glaxo Group Limited
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001089457	A2	20011129	WO 2001-US16863	20010524
	WO 2001089457	A3	20020307		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2411468	A1	20011129	CA 2001-2411468	20010524
	CA 2411468	C	20080415		
	AU 2001074938	A	20011203	AU 2001-74938	20010524
	EP 1294378	A2	20030326	EP 2001-941599	20010524
	EP 1294378	B1	20071003		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011116	A	20030408	BR 2001-11116	20010524
	CN 1444477	A	20030924	CN 2001-813340	20010524
	CN 100423721	C	20081008		
	HU 2003002257	A2	20031028	HU 2003-2257	20010524
	HU 2003002257	A3	20070328		
	JP 2003534257	T	20031118	JP 2001-585703	20010524
	JP 3813875	B2	20060823		
	NZ 522474	A	20041029	NZ 2001-522474	20010524
	NZ 533308	A	20051028	NZ 2001-533308	20010524
	AU 2001274938	B2	20060119	AU 2001-274938	20010524
	AT 374772	T	20071015	AT 2001-941599	20010524
	EP 1864981	A1	20071212	EP 2007-112105	20010524
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, SI				
	EP 1889838	A1	20080220	EP 2007-112106	20010524
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, SI				
	ES 2294000	T3	20080401	ES 2001-941599	20010524
	CN 101343250	A	20090114	CN 2008-10129758	20010524
	CN 101343251	A	20090114	CN 2008-10129759	20010524
	CN 101342169	A	20090114	CN 2008-10129760	20010524
	IL 152988	A	20090211	IL 2001-152988	20010524
	NO 2002005566	A	20030122	NO 2002-5566	20021120
	NO 324246	B1	20070917		
	IN 2002MN01666	A	20041211	IN 2002-MN1666	20021121
	KR 798568	B1	20080128	KR 2002-715869	20021123
	ZA 2002009561	A	20031020	ZA 2002-9561	20021125
	MX 2002011621	A	20040517	MX 2002-11621	20021125
	US 20040019190	A1	20040129	US 2003-296688	20030703
	US 7160870	B2	20070109		
	HK 1055561	A1	20080411	HK 2003-106428	20030909
	JP 2006137764	A	20060601	JP 2005-353686	20051207
	US 20070179192	A1	20070802	US 2006-558071	20061109

	US 7335649	B2	20080226		
	US 20070129338	A1	20070607	US 2007-620260	20070105
	US 7332481	B2	20080219		
	US 20080090996	A1	20080417	US 2007-650688	20070108
	US 7439342	B2	20081021		
	US 20080090787	A1	20080417	US 2007-650838	20070108
	US 7452874	B2	20081118		
	US 20080214640	A1	20080904	US 2007-650651	20070108
	US 7473686	B2	20090106		
	KR 2007087255	A	20070827	KR 2007-718036	20070806
	KR 847172	B1	20080717		
PRAI	US 2000-207084P	P	20000525		
	US 2000-228929P	P	20000830		
	CN 2001-813340	A3	20010524		
	EP 2001-941599	A3	20010524		
	JP 2001-585703	A3	20010524		
	WO 2001-US16863	W	20010524		
	KR 2002-715869	A3	20021123		
	US 2003-296688	A1	20030703		
OS	MARPAT 136:5987				
GI					



I

AB Pyrazolylidenehydrazino compds. such as I were prepared as thrombopoietin mimetics. Thus, I was prepared in 5 steps, the last of which involved reaction of 4-amino-3'-hydroxy-3-biphenylcarboxylic acid hydrochloride with 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-one.

IT 376592-42-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
((pyrazolylidenehydrazino)phenol derivs. as thrombopoietin mimetics)

RN 376592-42-6 CAPLUS

CN 3H-Pyrazol-3-one, 2-(3,4-dimethylphenyl)-2,4-dihydro-4-[2-[2-hydroxy-3'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]diazenyl]-5-methyl- (CA INDEX NAME)

```
=> => d que l8 stat
L5            16 SEA FILE=CAPLUS ABB=ON  PLU=ON  "BROOK CHRISTOPHER S"/AU
L6            11 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("PING LI JEN"/AU OR "PING LI
                 JEN J"/AU)
L7            25 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5 OR L6
L8             1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 AND (THROMBOPOIETIN OR TPO)


=> d bib abs
```

LS ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:405369 CAPLUS
DN 142:463730
TI Preparation of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline salt
IN Brook, Christopher S.; Ping, Li-Jen J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005041867	A2	20050512	WO 2004-US34944	20041021
WO 2005041867	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285462	A1	20050512	AU 2004-285462	20041021
CA 2543216	A1	20050512	CA 2004-2543216	20041021
EP 1684748	A2	20060802	EP 2004-796011	20041021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004015704	A	20061219	BR 2004-15704	20041021
CN 1897937	A	20070117	CN 2004-80038488	20041021
JP 2007509159	T	20070412	JP 2006-536801	20041021
IN 2006DN02031	A	20070622	IN 2006-DN2031	20060413
US 20070072922	A1	20070329	US 2006-576411	20060420
MX 2006004483	A	20060620	MX 2006-4483	20060421
KR 2006095761	A	20060901	KR 2006-707688	20060421
NO 2006002111	A	20060718	NO 2006-2111	20060511
PRAI US 2003-513481P	P	20031022		
WO 2004-US34944	W	20041021		

OS CASREACT 142:463730
GI



I

AB An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one (I), is prepared by treating 2-(3,4-dimethylphenyl)-4-[[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one with choline hydroxide. The

compound I is useful as an agonist of thrombopoietin receptor in enhancing platelet production, particularly in the treatment of thrombocytopenia. A tablet and injectable parenteral composition containing I are described.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l7 and ?pyrazol?
         81925 ?PYRAZOL?
L9           1 L7 AND ?PYRAZOL?

=> s l9 not l8
L10          0 L9 NOT L8

=> d his full

     (FILE 'HOME' ENTERED AT 09:12:02 ON 24 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 09:12:16 ON 24 MAR 2009
L1             STRUCTURE UPLOADED
               D
L2             0 SEA SSS SAM L1
L3             5 SEA SSS FUL L1
               D QUE L3 STAT
               D 1-5 IDE CAN

     FILE 'CAPLUS' ENTERED AT 09:14:59 ON 24 MAR 2009
L4            10 SEA ABB=ON  PLU=ON  L3
               D 1-10 BIB ABS HITSTR
               E BROOK CHRISTOPHER/AU
L5            16 SEA ABB=ON  PLU=ON  "BROOK CHRISTOPHER S"/AU
               E PING LI JEN/AU
L6            11 SEA ABB=ON  PLU=ON  ("PING LI JEN"/AU OR "PING LI JEN J"/AU)
L7            25 SEA ABB=ON  PLU=ON  L5 OR L6
L8             1 SEA ABB=ON  PLU=ON  L7 AND (THROMBOPOIETIN OR TPO)
               D QUE L8 STAT
               D BIB ABS
L9             1 SEA ABB=ON  PLU=ON  L7 AND ?PYRAZOL?
L10            0 SEA ABB=ON  PLU=ON  L9 NOT L8


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   22 MAR 2009  HIGHEST RN 1125392-64-4
     DICTIONARY FILE UPDATES:  22 MAR 2009  HIGHEST RN 1125392-64-4

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
```

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Mar 2009 VOL 150 ISS 13
FILE LAST UPDATED: 23 Mar 2009 (20090323/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	78.84	278.23
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.02	-9.02

STN INTERNATIONAL LOGOFF AT 09:21:55 ON 24 MAR 2009